New Low-Dose tdap vaccine trial aims to protect all ages
NCT ID NCT07418372
First seen Feb 26, 2026 · Last updated May 19, 2026 · Updated 18 times
Summary
This study tests a new version of the tetanus, diphtheria, and whooping cough (Tdap) vaccine that uses fewer active ingredients to reduce side effects. Researchers will enroll 660 volunteers aged 6 and older to check if the vaccine is safe and triggers a strong immune response. The trial is double-blind and compares the new vaccine to a standard one.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangjin District Center for Disease Control and Prevention
Chongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.